InflaRx NV IFRX.OQ, IFRX.O is expected to show a rise in quarterly revenue when it reports results on November 8 for the period ending September 30 2024
The Jena Thueringen-based company is expected to report a 34.5% increase in revenue to €81.75 thousand from €60.8 thousand a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for InflaRx NV is for a loss of 25 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for InflaRx NV is $7.50, above its last closing price of $1.60.
Previous quarterly performance (using preferred earnings measure in euros).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | -0.20 | -0.20 | -0.24 | Missed | -21.5 |
Jan. 1 2024 | -0.22 | -0.22 | -0.17 | Beat | 23.6 |
Dec. 31 2023 | -0.14 | -0.18 | -0.27 | Missed | -47.9 |
Sep. 30 2023 | -0.21 | -0.24 | -0.13 | Beat | 45.3 |
Jun. 30 2023 | -0.30 | -0.31 | -0.14 | Beat | 55.2 |
Mar. 31 2023 | -0.27 | -0.27 | -0.25 | Beat | 7.4 |
Dec. 31 2022 | -0.25 | -0.18 | Beat | 28 | |
Sep. 30 2022 | -0.33 | -0.32 | -0.18 | Beat | 44.6 |
This summary was machine generated November 6 at 14:13 GMT. All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments